Australia’s first infant RSV immunisation program linked to 57% drop in hospitalisations
WA funded a statewide nirsevimab program in April 2024.
Widespread use of nirsevimab in infants may reduce RSV-related hospitalisations by more than half, suggests a real-world study published in the Medical Journal of Australia.
WA’s State Government was the first to offer funded, statewide RSV immunisation with nirsevimab (Beyfortus) back in April 2024.
